Research ExplorerPublicationsComparison of Intensive Chemotherapy and Hypomethylating Age...

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

Standard

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. / Potter, Victoria T; Iacobelli, Simona; van Biezen, Anja; Maertens, Johann; Bourhis, Jean-Henri; Passweg, Jakob R; Yakhoub-Agha, Ibrahim; Tabrizi, Reza; Bay, Jacques-Olivier; Chevallier, Patrice; Chalandon, Yves; Huynh, Anne; Cahn, Jean Yves; Ljungman, Per; Craddock, Charles; Lenhoff, Stig; Russell, N H; Fegueux, Nathalie; Socié, Gerard; Benedetto, Bruno; Meijer, Ellen; Mufti, G J; de Witte, Theo; Robin, Marie; Kröger, Nicolaus.

In: BIOL BLOOD MARROW TR, Vol. 22, No. 9, 09.2016, p. 1615-1620.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Potter, VT, Iacobelli, S, van Biezen, A, Maertens, J, Bourhis, J-H, Passweg, JR, Yakhoub-Agha, I, Tabrizi, R, Bay, J-O, Chevallier, P, Chalandon, Y, Huynh, A, Cahn, JY, Ljungman, P, Craddock, C, Lenhoff, S, Russell, NH, Fegueux, N, Socié, G, Benedetto, B, Meijer, E, Mufti, GJ, de Witte, T, Robin, M & Kröger, N 2016, 'Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research', BIOL BLOOD MARROW TR, vol. 22, no. 9, pp. 1615-1620. https://doi.org/10.1016/j.bbmt.2016.05.026

APA

Potter, V. T., Iacobelli, S., van Biezen, A., Maertens, J., Bourhis, J-H., Passweg, J. R., Yakhoub-Agha, I., Tabrizi, R., Bay, J-O., Chevallier, P., Chalandon, Y., Huynh, A., Cahn, J. Y., Ljungman, P., Craddock, C., Lenhoff, S., Russell, N. H., Fegueux, N., Socié, G., ... Kröger, N. (2016). Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. BIOL BLOOD MARROW TR, 22(9), 1615-1620. https://doi.org/10.1016/j.bbmt.2016.05.026

Vancouver

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis J-H, Passweg JR et al. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. BIOL BLOOD MARROW TR. 2016 Sep;22(9):1615-1620. https://doi.org/10.1016/j.bbmt.2016.05.026

Bibtex

@article{21cd7edd0ade4bcfb238060bdba3763a,
title = "Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research",
abstract = "The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syndromes. Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than > 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM (26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR (68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS (hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P = .001), RFS (HR, 2.27; 95% CI, 1.37 to 3.76; P = .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA group.",
keywords = "Journal Article",
author = "Potter, {Victoria T} and Simona Iacobelli and {van Biezen}, Anja and Johann Maertens and Jean-Henri Bourhis and Passweg, {Jakob R} and Ibrahim Yakhoub-Agha and Reza Tabrizi and Jacques-Olivier Bay and Patrice Chevallier and Yves Chalandon and Anne Huynh and Cahn, {Jean Yves} and Per Ljungman and Charles Craddock and Stig Lenhoff and Russell, {N H} and Nathalie Fegueux and Gerard Soci{\'e} and Bruno Benedetto and Ellen Meijer and Mufti, {G J} and {de Witte}, Theo and Marie Robin and Nicolaus Kr{\"o}ger",
note = "Copyright {\textcopyright} 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = sep,
doi = "10.1016/j.bbmt.2016.05.026",
language = "English",
volume = "22",
pages = "1615--1620",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

AU - Potter, Victoria T

AU - Iacobelli, Simona

AU - van Biezen, Anja

AU - Maertens, Johann

AU - Bourhis, Jean-Henri

AU - Passweg, Jakob R

AU - Yakhoub-Agha, Ibrahim

AU - Tabrizi, Reza

AU - Bay, Jacques-Olivier

AU - Chevallier, Patrice

AU - Chalandon, Yves

AU - Huynh, Anne

AU - Cahn, Jean Yves

AU - Ljungman, Per

AU - Craddock, Charles

AU - Lenhoff, Stig

AU - Russell, N H

AU - Fegueux, Nathalie

AU - Socié, Gerard

AU - Benedetto, Bruno

AU - Meijer, Ellen

AU - Mufti, G J

AU - de Witte, Theo

AU - Robin, Marie

AU - Kröger, Nicolaus

N1 - Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2016/9

Y1 - 2016/9

N2 - The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syndromes. Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than > 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM (26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR (68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS (hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P = .001), RFS (HR, 2.27; 95% CI, 1.37 to 3.76; P = .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA group.

AB - The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syndromes. Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than > 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM (26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR (68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS (hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P = .001), RFS (HR, 2.27; 95% CI, 1.37 to 3.76; P = .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA group.

KW - Journal Article

U2 - 10.1016/j.bbmt.2016.05.026

DO - 10.1016/j.bbmt.2016.05.026

M3 - SCORING: Journal article

C2 - 27264633

VL - 22

SP - 1615

EP - 1620

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 9

ER -